Suppr超能文献

基于监测、流行病学和终期结果的分析,探讨术前或术后放疗对 T3N0 直肠癌患者生存结局的影响。

Surveillance, epidemiology, and end results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer.

机构信息

Department of Radiation Oncology, Stich Radiation Center, Weill Cornell Medical College of Cornell University, New York, NY, United States.

Department of Surgery, Weill Cornell Medical College of Cornell University, New York, NY, United States.

出版信息

Cancer Epidemiol. 2014 Feb;38(1):73-8. doi: 10.1016/j.canep.2013.12.008. Epub 2014 Feb 1.

Abstract

PURPOSE

Preoperative chemoradiation has been established as standard of care for T3/T4 node-positive rectal cancer. Recent work, however, has called into question the overall benefit of radiation for tumors with lower risk characteristics, particularly T3N0 rectal cancers. We retrospectively analyzed T3N0 rectal cancer patients and examined how outcomes differed according to the sequence of treatment received.

METHODS

The Surveillance, Epidemiology, and End Results (SEER) database was used to analyze T3N0 rectal cancer cases diagnosed between 1998 and 2008. Treatment consisted of surgery alone (No RT), preoperative radiation followed by surgery (Neo-Adjuvant RT), or surgery followed by postoperative radiation (Adjuvant RT). Demographic and tumor characteristics of the three groups were compared using t-tests for the comparison of means. Survival information from the SEER database was utilized to estimate cause-specific survival (CSS) and to generate Kaplan-Meier survival curves. Multivariate analysis (MVA) of features associated with outcomes was conducted using Cox proportional hazards regression models with Adjuvant RT, Neo-Adjuvant RT, No RT, histological grade, tumor size, year of diagnosis, and demographic characteristics as covariates.

RESULTS

10-Year CSS estimates were 66.1% (95% CI 62.3-69.6%; P=0.02), 73.5% (95% CI 68.9-77.5%; P=0.02), and 76.1% (95% CI 72.4-79.4%; P=0.02), for No RT, Neo-Adjuvant RT, and Adjuvant RT, respectively. On MVA, Adjuvant RT (HR=0.688; 95% CI, 0.578-0.819; P<0.001) was associated with significantly decreased risk for cancer death. By contrast, Neo-Adjuvant RT was not significantly associated with improved cancer survival (HR=0.863; 95% CI, 0.715-1.043; P=0.127).

CONCLUSION

Adjuvant RT was associated with significantly higher CSS when compared with surgery alone, while the benefit of Neo-Adjuvant RT was not significant. This indicates that surgery followed by Adjuvant RT may still be an important treatment plan for T3N0 rectal cancer with potentially significant survival advantages over other treatment sequences.

摘要

目的

术前放化疗已被确立为 T3/T4 淋巴结阳性直肠癌的标准治疗方法。然而,最近的研究工作对放疗对风险特征较低的肿瘤的整体益处提出了质疑,特别是 T3N0 直肠癌。我们回顾性分析了 T3N0 直肠癌患者,并研究了根据所接受的治疗顺序,结果有何不同。

方法

利用监测、流行病学和最终结果(SEER)数据库分析了 1998 年至 2008 年间诊断的 T3N0 直肠癌病例。治疗包括单纯手术(无放疗)、术前放疗后手术(新辅助放疗)或手术后放疗(辅助放疗)。使用 t 检验比较三组患者的人口统计学和肿瘤特征。利用 SEER 数据库中的生存信息,利用特定原因生存(CSS)估计和生成 Kaplan-Meier 生存曲线来估计生存情况。使用 Cox 比例风险回归模型对与结果相关的特征进行多变量分析(MVA),并将辅助放疗、新辅助放疗、无放疗、组织学分级、肿瘤大小、诊断年份和人口统计学特征作为协变量。

结果

10 年 CSS 估计值分别为无放疗组 66.1%(95%CI 62.3-69.6%;P=0.02)、新辅助放疗组 73.5%(95%CI 68.9-77.5%;P=0.02)和辅助放疗组 76.1%(95%CI 72.4-79.4%;P=0.02)。在 MVA 中,辅助放疗(HR=0.688;95%CI,0.578-0.819;P<0.001)与癌症死亡风险显著降低相关。相比之下,新辅助放疗与癌症生存的改善无显著相关性(HR=0.863;95%CI,0.715-1.043;P=0.127)。

结论

与单纯手术相比,辅助放疗显著提高了 CSS,而新辅助放疗的益处并不显著。这表明,手术后辅助放疗可能仍是 T3N0 直肠癌的重要治疗方案,与其他治疗序列相比,可能具有显著的生存优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验